On June 27, 2023, the 2022 top 100 lists of China's pharmaceutical industry were released in Huzhou, Zhejiang Province.Fosun Pharma (Stock Code: 600196.SH, 02196.HK) was successfully ranked in the list of "China's Top 100 Chemical Pharmaceutical Companies in 2022"with its global R&D and pharmaceutical manufacturing capabilities and professional commercialization ability, ranking 6th among the top 100 Chinese pharmaceutical companies!

The top 100 lists of China's pharmaceutical industry were released by Menet Research Institute, which organized an expert committee for the selection. The experts rely on Menet’s professional database, and select the nominee from the two most important dimensions (innovation driving force and professional promotion capacity). The "2022 Top 100 Lists of China's pharmaceutical industry" are divided into five sub-lists: "List of Top 100 Chinese chemical pharmaceutical enterprises", "List of Top 100 Chinese traditional Chinese medicine enterprises", "List of Top 20 Chinese CXO enterprises", "List of Top 20 Chinese medical device (including IVD) enterprises", and "List of Top 20 Chinese biomedical (including blood products, vaccines, and insulin) enterprises".

In addition, the Chinese government frequently issued policies of "propelling and stabilizing economic growth" in 2023, stimulating the industrial enthusiasm for new drug R&D. Enterprises spare no effort to innovate and long for better results. China's biomedical industry needs the technological enhancement and a shift from following others to keeping pace and even leading the pack. To this end, Menet launched the selection activity for the “2022 List of Top 100 Chinese biomedical innovative enterprises".

Among them,Henlius, a subsidiary of Fosun Pharma, and Fosun Kite, a joint venture established by Fosun Pharma and Kite Pharma, were successfully selected into the "2022 Top 30 Chinese antibody drug innovative enterprises" and the "2022 Top 30 Chinese new technology drug innovative enterprises".

Founded in 1994, after nearly 30 years of development, Fosun Pharma has become a global innovation-driven pharmaceutical and healthcare industry group. Its directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “Innovation Transformation, Integrated Operation and Steady Growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets.

***